Shield Therapeutics (AIM: STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency with Feraccru®. Following IPO and EU approval of Feraccru, both in February 2016, STX has made good progress with its clinical and commercial strategy, most recently demonstrating in a phase 3 trial that oral Feraccru is as effective as intravenous iron. Management has secured commercialisation agreements and is now awaiting an FDA decision in 3Q’19. The remaining risks lie in US approval and in successful execution of commercialisation.
13 May 2019
All in the execution
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
All in the execution
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-0.3%) | Mkt Cap: 11.5m
- Published:
13 May 2019 -
Author:
Martin Hall -
Pages:
32
Shield Therapeutics (AIM: STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency with Feraccru®. Following IPO and EU approval of Feraccru, both in February 2016, STX has made good progress with its clinical and commercial strategy, most recently demonstrating in a phase 3 trial that oral Feraccru is as effective as intravenous iron. Management has secured commercialisation agreements and is now awaiting an FDA decision in 3Q’19. The remaining risks lie in US approval and in successful execution of commercialisation.